Table 2.
Clinical and molecular data of GBM patients enrolled for GEC isolation.
| Age | Sex | Tumor location | KPS | IDH | MGMT | Ki-67 | |
|---|---|---|---|---|---|---|---|
| GEC09 | 81 | F | FP left | 60 | wt | 4% | 15% |
| GEC182 | 41 | F | T left | 70 | wt | 49% | 55% |
| GEC183 | 41 | M | T right | 80 | wt | 14% | 40% |
| GEC187 | 45 | M | FR right | 100 | wt | 37% | 20% |
| GEC208 | 60 | M | P right | 80 | wt | 14% | 30% |
| GEC210 | 52 | M | P left | 70 | wt | 15% | 55% |
| GEC214 | 66 | M | T left | 80 | wt | 60% | 65% |
| GEC231 | 82 | F | T left | 70 | wt | 3% | 27% |
| GEC233 | 80 | M | T right | 80 | wt | 2% | 40% |
M, male; F, female; T, temporal lobe; I, insular lobe; FR, frontal lobe; P, parietal lobe; KPS, Karnofsky performance status; MGMT, O6-methylguanine-DNA methyltransferase; IDH, isocitrate dehydrogenase; Ki-67, proliferation index.